A Retrospective Study on Experience of High-flow Nasal Cannula Oxygen in Critically Ill COVID-19 Adult Patients Admitted to Intensive Care Unit
Sukhyanti Kerai, Rahil Singh, Kirti N Saxena, Suraj D Desai, Anju R Bhalotra
Acute hypoxemic respiratory failure (AHRF), COVID-19, High-flow nasal cannula (HFNC) oxygen therapy, Intensive care unit
Citation Information :
Kerai S, Singh R, Saxena KN, Desai SD, Bhalotra AR. A Retrospective Study on Experience of High-flow Nasal Cannula Oxygen in Critically Ill COVID-19 Adult Patients Admitted to Intensive Care Unit. Indian J Crit Care Med 2022; 26 (1):62-66.
Background: The use of high-flow nasal cannula (HFNC) in coronavirus disease-2019 (COVID-19) patients is debated due to its uncertain benefits and risks of aerosol dispersion. This retrospective study was aimed to assess the outcome of treatment with HFNC therapy in adult COVID-19 patients with acute hypoxemic respiratory failure (AHRF) admitted in intensive care units (ICU) and to assess the factors affecting outcome.
Material and methods: We retrieved electronic medical records of all COVID-19 patients who received HFNC for respiratory support after failure to maintain adequate oxygenation with conventional oxygen devices, between June 1 and August 31, 2020. The data retrieved were statistically analyzed.
Results: A total number of 558 COVID-19 patients were admitted to ICUs, out of which 139 patients were identified to be on HFNC and 85 met the inclusion criteria for the study. The success rate of 48.2% with HFNC was observed in these patients. The patients recorded to experience HFNC success were of young age and having higher baseline oxygen saturation compared to those who had its failure. The ROX indices post-initiation were observed to be significantly higher in the success group (p ≤0.001). Awake-prone positioning while receiving HFNC was followed by around more patients in the success group (p <0.001). On multivariate logistic regression analysis, baseline oxygen saturation, awake-prone positioning, and number of days on HFNC were found to be independently affected outcome with HFNC.
Conclusion: Almost half of the cases of moderate-to-severe COVID-19 pneumonia can be managed successfully with HFNC, without the need of mechanical ventilation.
Miller IF, Becker AD, Grenfell BT, Metcalf JE. Disease and healthcare burden of COVID-19 in the United States. Nat Med 2020;26(8): 1212–1217. DOI: 10.1038/s41591-020-0952-y.
Sahoo H, Mandal C, Mishra S, Banerjee S. Burden of COVID-19 pandemic in India: perspectives from health infrastructure. medRxiv 2020. DOI: 10.1101/2020.05.26.20113456.
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life- threatening COVID-19. JAMA 2020;324(5):1–11. DOI: 10.1001/jama.2020.10044.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomized, double- blind, placebo-controlled, multicentre trial. Lancet 2020;395(10236):1569–1578. DOI: 10.1016/S0140-6736(20)31022-9.
Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med 2020;e206319. DOI: 10.1001/jamainternmed.2020.6319.
Rochwerg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med 2019;45(5):563–572. DOI: 10.1007/s00134-019-05590-5.
Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372(23):2185–2196. DOI: 10.1056/NEJMoa1503326.
Alhazzani W, Moller MH, Arabi YH. Surviving sepsis campaign: guidelines on the management of critically ill adults with Coronavirus disease-2019 (COVID-19). Intensive Care Med 2020;46(5):854–887. DOI: 10.1007/s00134-020-06022-5.
ANZICS COVID-19 Working Group. The Australian and New Zealand Intensive Care Society COVID-19 Guidelines (Version 1; March 16, 2020). Available from: www.anzics.com.au/wp-content/uploads/2020/03/ANZICS-COVID-19-Guidelines-Version-1.pdf [accessed November 23, 2020].
Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J 2020;55(5):2000892. DOI: 10.1183/13993003.00892-2020.
Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Medicine 2020;46(6):1099–1102. DOI: 10.1007/s00134-020-06033-2.
Matta SK. Dilemmas in COVID-19 respiratory distress: early vs late intubation: high tidal volume and low PEEPVs traditional approach? J Intensive Crit Care 2020;6(2):7. DOI: 10.36648/2471-8505.6.2.7.
Hernandez-Romieu AC, Adelman MW, Hockstein MA, Robichaux CJ, Edwards JA, Fazio JC. Timing of intubation and mortality among critically ill coronavirus disease-2019 patients: a single centre cohort study. Crit Care Med 2020;48(11):e1045. DOI: 10.1097/CCM.0000000000004600.
Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernandez G, et al. An index combining respiratory rate and oxygenation to predict outcomes of nasal high-flow therapy. Am J Respir Crit Care Med 2019;199(11):1368–1376. DOI: 10.1164/rccm.201803-0589OC.
Calligro GL, Lalla U, Audley G, Gina P, Miller MG, Mendelson M, et al. The utility of high flow nasal oxygen for severe COVID-19 pneumonia in a resource constrained setting: a multi-centre prospective observational study. Lancet 2020;28:100570. DOI: 10.1016/j.eclinm.2020.100570.
Thomson AE, Ranard BL, Wei Y, Jelic S. Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure. JAMA Intern Med 2020;80(11):1537–1539. DOI: 10.1001/jamainternmed.2020.3030.
Solverson K, Weather J, Parhar KKS. Tolerability and safety of awake prone positioning COVID-19 patients with severe hypoxemic respiratory failure. Can J Anaesth 2020;68(1);1–7. DOI: 10.1007/s12630-020-01787-1.
Koeckerling D, Barker J, Mudalige NL, Oyefeso O, Pan D, Parek M, et al. Awake prone positioning in COVID-19. Thorax 2020;75(10):833–834. DOI: 10.1136/thoraxjnl-2020-215133.
Demoule A, Baron AV, Darmon M, Beurton A, Geri G, Voiriot G, et al. High flow nasal cannula in critically ill patients with severe covid-19. Am J Respir Crit Care 2020;202(7):1039–1042. DOI: 10.1164/rccm.202005-2007LE.
Patel M, Gangemi A, Marron R, Chowdhury J, Yousef I, Zheng M, et al. Retrospective analysis of high flow nasal therapy in COVID-19 related moderate-to-severe hypoxaemic respiratory failure. BMJ Open Resp Res 2020;7:e000650. DOI:10.1136/bmjreso-2020-000650.
Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care 2020;10(1):37. DOI: 10.1186/s13613-020-00653-z.
Li Y, Zhao K, Wei H, Chen W, Wang W, Jia L, et al. Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol 2020;190(1):e24. DOI: 10.1111/bjh.16811.
Yu B, Li X, Chen J, Ouyang M, Zhang H, Zhao X, et al. Evaluation of variation in d dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis 2020;50(3):548–547. DOI: 10.1007/s11239-020-02171-y.
Sisniehuez CEL, Espeche WG, Salazar MR. Arterial hypertension and the risk of severity and mortality of COVID-19. Eur Respir J 2020;55(6):2001148. DOI: 10.1183/13993003.01148-2020.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease-2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese centre for disease control and prevention. JAMA 2020;323(13):1239–1242. DOI: 10.1001/jama.2020.2648.
Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, et al. Exhaled air dispersion during high flow nasal cannula therapy versus CPAP via different masks. Eur Respir J 2019;53(4):1802339. DOI: 10.1183/13993003.02339-2018.
Leung CCH, Joynt GM, Gomersall CD, Wong WT, Lee A, Ling L, et al. Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial. J Hosp Infect 2019;101(1):84–87. DOI: 10.1016/j.jhin.2018.10.007.
Gaeckle NT, Lee J, Park Y, Kreykes G, Evans MD, Hogan Jr CJ. Aerosol generation from respiratory tract with various modes of oxygen delivery. Am J Respir Crit Care Med 2020;202(8):1115–1124. DOI: 10.1164/rccm.202006-2309OC.
Lyon C, Callaghan M. The use of high-flow nasal oxygen in COVID-19. Anaesthesia 2020;75(7):843–847. DOI: 10.1111/anae.15073.
Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physician. Am J Respir Crit Care Med 2020;202(3):356–360. DOI: 10.1164/rccm.202006-2157CP.
Xie J, Covassin N, Fan Z, Singh P, Gao W, Li G, et al. Association between hypoxemia and mortality in patients with COVID-19. Mayo Clin Proc 2020;95(6):1138–1147. DOI: 10.1016/j.mayocp.2020.04.006.
Kashani KB. Hypoxia in COVID-19: sign of severity or cause of poor outcome. Mayo Clin Proc 2020;95(6):1094–1096. DOI: 10.1016/j.mayocp.2020.04.021.